Skip to main content
Premium Trial:

Request an Annual Quote

Covance Buys Caprion Proteomics Equity Stake

NEW YORK (GenomeWeb News) – Princeton, NJ-based drug development services company Covance announced yesterday that it has purchased an undisclosed minority stake in the proteomics-based pharmaceutical services company Caprion Proteomics.
Under the agreement, Covance will use Caprion as its exclusive proteomic discovery provider and will act as the exclusive contract research organization distributor for Caprion’s proteomic biomarker services.
The move is aimed at augmenting the biomarker services Covance offers its pharmaceutical and biotechnology drug development customers. The biomarker discovery, validation, and deployment efforts are aimed at improving drug discovery, approval, and monitoring — spanning proof-of-concept studies to clinical trials and post-marketing surveillance.
Covance also announced that it intends to establish a Biomarker Center of Excellence, which will focus on biomarker testing and validation, at its Greenfield, Ind., campus. Former Pfizer scientist Thomas Turi, who was recently hired as vice president of biomarkers for Covance, will lead the new center.

The Scan

Harvard Team Report One-Time Base Editing Treatment for Motor Neuron Disease in Mice

A base-editing approach restored SMN levels and improved motor function in a mouse model of spinal muscular atrophy, a new Science paper reports.

International Team Examines History of North American Horses

Genetic and other analyses presented in Science find that horses spread to the northern Rockies and Great Plains by the first half of the 17th century.

New Study Examines Genetic Dominance Within UK Biobank

Researchers analyze instances of genetic dominance within UK Biobank data, as they report in Science.

Cell Signaling Pathway Identified as Metastasis Suppressor

A new study in Nature homes in on the STING pathway as a suppressor of metastasis in a mouse model of lung cancer.